A shift in the treatment of CKD associated with type 2 diabetes mellitus (T2DM) has been made since the first clinical trial showing the benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors was published in 2015. This evidence concerns the gene SLC5A2 and chronic kidney disease.